Two approaches to growth hormone secretion. One's a broad anti-aging stack, the other targets belly fat with FDA backing.
Bottom line: These serve different goals. CJC/Ipa is the 'feel better, sleep better, recover faster' stack that most anti-aging clinics default to. Tesamorelin is the 'I need to reduce visceral fat and I want real clinical data behind it' choice. If stubborn belly fat is the problem, tesamorelin has the data. For everything else — sleep, recovery, general vitality — CJC/Ipa covers more ground.
| CJC-1295/Ipamorelin | Tesamorelin | |
|---|---|---|
| Category | GHRH analog + GH secretagogue (combo) | GHRH analog (solo) |
| Mechanism | CJC-1295 stimulates GHRH receptors while ipamorelin hits ghrelin receptors — dual-pathway GH pulse | Stabilized GHRH(1-44) analog that stimulates natural GH release through a single pathway |
| Reported dose | CJC-1295: 100–300 mcg + Ipamorelin: 100–300 mcg, combined per injection | 2 mg daily subcutaneous injection |
| Frequency | Daily (before bed) or 5 days on/2 off | Once daily |
| Weight loss (trials) | Not primarily a weight loss peptide — indirect fat loss through improved body composition | 15–18% visceral fat reduction in clinical trials (HIV lipodystrophy) |
| Top side effect | Water retention, tingling/numbness in hands, vivid dreams, mild joint pain | Joint pain, swelling, injection site reactions, muscle pain |
| Evidence tier | Tier 2–3 — CJC-1295 has some human PK data, ipamorelin has Phase 2 data, the combo is largely clinic-driven | Tier 1 — FDA-approved with completed Phase 3 trials |
| Common vial size | 2 mg or 5 mg vials (typically pre-mixed blend) | 2 mg vials (branded: Egrifta) |
| Approval status | Not FDA-approved. Both moved to Category 1 (Feb 2026) | FDA-approved as Egrifta for HIV-associated lipodystrophy |
CJC/Ipa is the move if your goals are broad — better sleep, recovery, body composition, and general anti-aging. The dual-pathway mechanism produces more natural GH pulses than either peptide alone. It is also more accessible and cheaper than tesamorelin.
Tesamorelin is the clinical choice when visceral fat is the specific target. It is the only peptide with FDA-level evidence for belly fat reduction (15–18%). If you want the strongest evidence base and are specifically trying to reduce abdominal fat, tesamorelin is the move.
These serve different goals. CJC/Ipa is the 'feel better, sleep better, recover faster' stack that most anti-aging clinics default to. Tesamorelin is the 'I need to reduce visceral fat and I want real clinical data behind it' choice. If stubborn belly fat is the problem, tesamorelin has the data. For everything else — sleep, recovery, general vitality — CJC/Ipa covers more ground.
← Browse all peptides | All comparisons →
vialprep research · Sources: PubMed, FDA, peer-reviewed trials · How we verify